S&P 500   3,329.93 (+1.80%)
DOW   26,794.98 (+1.04%)
QQQ   278.19 (+2.41%)
AAPL   116.42 (+4.69%)
MSFT   206.18 (+1.73%)
FB   280.51 (+4.80%)
GOOGL   1,573.27 (+4.13%)
AMZN   3,225.64 (+1.99%)
TSLA   413.15 (+1.76%)
NVDA   523.52 (+3.65%)
BABA   314.45 (+2.11%)
CGC   18.87 (+2.89%)
GE   7.39 (-0.40%)
MU   50.63 (+1.26%)
AMD   78.40 (+2.62%)
T   26.86 (+1.36%)
F   7.95 (+3.25%)
ACB   4.08 (+6.53%)
GILD   58.75 (+0.05%)
NFLX   508.16 (+4.51%)
NIO   32.00 (+16.32%)
BA   148.34 (+0.14%)
DIS   122.16 (+3.11%)
S&P 500   3,329.93 (+1.80%)
DOW   26,794.98 (+1.04%)
QQQ   278.19 (+2.41%)
AAPL   116.42 (+4.69%)
MSFT   206.18 (+1.73%)
FB   280.51 (+4.80%)
GOOGL   1,573.27 (+4.13%)
AMZN   3,225.64 (+1.99%)
TSLA   413.15 (+1.76%)
NVDA   523.52 (+3.65%)
BABA   314.45 (+2.11%)
CGC   18.87 (+2.89%)
GE   7.39 (-0.40%)
MU   50.63 (+1.26%)
AMD   78.40 (+2.62%)
T   26.86 (+1.36%)
F   7.95 (+3.25%)
ACB   4.08 (+6.53%)
GILD   58.75 (+0.05%)
NFLX   508.16 (+4.51%)
NIO   32.00 (+16.32%)
BA   148.34 (+0.14%)
DIS   122.16 (+3.11%)
S&P 500   3,329.93 (+1.80%)
DOW   26,794.98 (+1.04%)
QQQ   278.19 (+2.41%)
AAPL   116.42 (+4.69%)
MSFT   206.18 (+1.73%)
FB   280.51 (+4.80%)
GOOGL   1,573.27 (+4.13%)
AMZN   3,225.64 (+1.99%)
TSLA   413.15 (+1.76%)
NVDA   523.52 (+3.65%)
BABA   314.45 (+2.11%)
CGC   18.87 (+2.89%)
GE   7.39 (-0.40%)
MU   50.63 (+1.26%)
AMD   78.40 (+2.62%)
T   26.86 (+1.36%)
F   7.95 (+3.25%)
ACB   4.08 (+6.53%)
GILD   58.75 (+0.05%)
NFLX   508.16 (+4.51%)
NIO   32.00 (+16.32%)
BA   148.34 (+0.14%)
DIS   122.16 (+3.11%)
S&P 500   3,329.93 (+1.80%)
DOW   26,794.98 (+1.04%)
QQQ   278.19 (+2.41%)
AAPL   116.42 (+4.69%)
MSFT   206.18 (+1.73%)
FB   280.51 (+4.80%)
GOOGL   1,573.27 (+4.13%)
AMZN   3,225.64 (+1.99%)
TSLA   413.15 (+1.76%)
NVDA   523.52 (+3.65%)
BABA   314.45 (+2.11%)
CGC   18.87 (+2.89%)
GE   7.39 (-0.40%)
MU   50.63 (+1.26%)
AMD   78.40 (+2.62%)
T   26.86 (+1.36%)
F   7.95 (+3.25%)
ACB   4.08 (+6.53%)
GILD   58.75 (+0.05%)
NFLX   508.16 (+4.51%)
NIO   32.00 (+16.32%)
BA   148.34 (+0.14%)
DIS   122.16 (+3.11%)
Log in
NASDAQ:PACB

Pacific Biosciences of California Stock Forecast, Price & News

$13.28
-0.69 (-4.94 %)
(As of 10/29/2020 03:40 PM ET)
Add
Compare
Today's Range
$13.28
Now: $13.28
$14.19
50-Day Range
$6.51
MA: $10.96
$14.95
52-Week Range
$2.20
Now: $13.28
$15.12
Volume137,484 shs
Average Volume2.57 million shs
Market Capitalization$2.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Read More
Pacific Biosciences of California logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.04 out of 5 stars

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000
Employees401

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.89 million
Book Value$0.36 per share

Profitability

Net Income$-84,130,000.00

Miscellaneous

Market Cap$2.05 billion
Next Earnings Date11/2/2020 (Confirmed)
OptionableOptionable
$13.28
-0.69 (-4.94 %)
(As of 10/29/2020 03:40 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

How has Pacific Biosciences of California's stock price been impacted by COVID-19 (Coronavirus)?

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PACB stock has increased by 286.0% and is now trading at $13.28.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Pacific Biosciences of California?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pacific Biosciences of California
.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Pacific Biosciences of California
.

How can I listen to Pacific Biosciences of California's earnings call?

Pacific Biosciences of California will be holding an earnings conference call on Monday, November 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings data on Monday, August, 3rd. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.04. The biotechnology company earned $17.08 million during the quarter, compared to analysts' expectations of $13.84 million. Pacific Biosciences of California had a negative net margin of 61.85% and a negative return on equity of 150.00%.
View Pacific Biosciences of California's earnings history
.

What price target have analysts set for PACB?

5 analysts have issued 1-year target prices for Pacific Biosciences of California's shares. Their forecasts range from $7.00 to $17.00. On average, they anticipate Pacific Biosciences of California's share price to reach $11.60 in the next twelve months. This suggests that the stock has a possible downside of 12.7%.
View analysts' price targets for Pacific Biosciences of California
.

Who are some of Pacific Biosciences of California's key competitors?

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), InVitae (NVTA) and Tesla (TSLA).

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the following people:
  • Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)
  • Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)
  • Mr. James Michael Phillips, Sr. VP of R&D (Age 68)
  • Dr. Stephen Turner, Co-Founder & CTO (Age 51)
  • Dr. Jonas Korlach Ph.D., Chief Scientific Officer

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.56%), Moloney Securities Asset Management LLC (0.05%), Archford Capital Strategies LLC (0.04%), Havens Advisors LLC (0.04%), Dynamic Advisor Solutions LLC (0.02%) and Cambridge Investment Research Advisors Inc. (0.01%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes.
View institutional ownership trends for Pacific Biosciences of California
.

Which major investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including Havens Advisors LLC, Assenagon Asset Management S.A., and Moloney Securities Asset Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Michael Hunkapiller, and Susan K Barnes.
View insider buying and selling activity for Pacific Biosciences of California
.

Which major investors are buying Pacific Biosciences of California stock?

PACB stock was acquired by a variety of institutional investors in the last quarter, including Archford Capital Strategies LLC, Dynamic Advisor Solutions LLC, Cambridge Investment Research Advisors Inc., Nisa Investment Advisors LLC, and Clear Harbor Asset Management LLC.
View insider buying and selling activity for Pacific Biosciences of California
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $13.28.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $2.05 billion and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is www.pacb.com.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.